BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced results published in a review article exploring the potential efficacy of Deep Transcranial Magnetic Stimulation (Deep TMS) as a novel therapeutic approach for Parkinson's Disease (PD). The paper was published in Frontiers of Human Neuroscience, a leading peer-reviewed journal focused on advancing the understanding of brain mechanisms in both healthy and diseased states.

The review summarizes data from six different studies involving an aggregate total of 220 patients, including a substantial number of patients who were administered a two-stage Deep TMS protocol addressing prefrontal and motor targets. Clinically meaningful improvements in motor symptoms were generally observed, and in those studies which assessed non-motor symptoms, improvements in daily living and mood symptoms were reported. Four of the studies also noted that severe patients benefited most from the treatment. Deep TMS was generally well-tolerated across all of the studies.

"This clinical review marks an important step forward in our understanding of the potential benefits of Deep TMS for those suffering from Parkinson's Disease," said Colleen Hanlon, Ph.D., Vice President of Medical and Clinical Affairs at BrainsWay. "The two-stage H-Coil protocol is an innovative approach to address multiple symptoms of the disease. While further research is needed in this area, possible benefits of Deep TMS for PD patients may include improved cognitive function, reduced side effect burden relative to drugs, and enhanced quality of life."

BrainsWay Deep TMS is not cleared by the FDA as a safe and/or effective treatment for Parkinson's Disease.